Lansoprazole

Contraindicated

Lansoprazole Rilpivirine Edurant Reduced oral rilpivirine exposure, reduced efficacy of rilpivirine and an increased loss of virologic response Details

Major

Lansoprazole Acalabrutinib Calquence Reduced acalabrutinib exposure Details Lansoprazole Belumosudil Rezurock Reduced belumosudil exposure Details Lansoprazole Atezolizumab Injection Tecentriq Impaired efficacy of atezolizumab Details Lansoprazole Bosutinib Bosulif Reduced bosutinib exposure Details Lansoprazole Capecitabine Xeloda Reduction in capecitabine efficacy Details Lansoprazole Cefuroxime Ceftin® Decreased cefuroxime axetil exposure Details Lansoprazole Dacomitinib Vizimpro Reduced dacomitinib exposure Details Lansoprazole Dasatinib Phyrago Reduced dasatinib exposure Details Lansoprazole Digoxin Cardoxin® An increased digoxin exposure Details Lansoprazole Erlotinib Tarceva Reduced erlotinib exposure Details Lansoprazole Gefitinib Iressa Decreased exposure of gefitinib Details Lansoprazole Infigratinib Truseltiq Decreased infigratinib plasma concentrations Details Lansoprazole Ketoconazole Topical Extina® Foam Reduced ketoconazole exposure and reduced efficacy of ketoconazole Details Lansoprazole Amphetamine Dexedrine Increased exposure to amphetamine Details Lansoprazole Apalutamide Erleada Reduced CYP2C19 substrate exposure Details Lansoprazole Atazanavir Reyataz Reduced atazanavir exposure, reduced efficacy of atazanavir and development of resistance Details Lansoprazole Atezolizumab Tecentriq Impaired efficacy of atezolizumab Details Lansoprazole Benzphetamine Increased exposure to amphetamine Details Lansoprazole Cannabidiol Epidiolex Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse reactions Details Lansoprazole Carbamazepine Carbatrol Reduced CYP2C19 substrate exposure and reduced efficacy of CYP2C19 substrate Details Lansoprazole Cefuroxime Axetil Decreased cefuroxime axetil exposure Details Lansoprazole Cilostazol Pletal® Increased cilostazol exposure Details Lansoprazole Citalopram Celexa Increased citalopram exposure and an increased risk of QT interval prolongation Details Lansoprazole Dabrafenib Tafinlar Reduced CYP2C19 sensitive substrate exposure Details Lansoprazole Defactinib Reduced defactinib exposure and an reduced efficacy of defactinib Details Lansoprazole Delavirdine Rescriptor® Reduced serum delavirdine levels Details Lansoprazole Dextroamphetamine Dexedrine Increased exposure to amphetamine Details Lansoprazole Eslicarbazepine Acetate Aptiom Increased exposure of CYP2C19 substrates Details Lansoprazole Fedratinib Inrebic Increased CYP2C19 substrate exposure Details Lansoprazole Fluconazole Diflucan Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse events Details Lansoprazole Ketoconazole Extina Reduced ketoconazole exposure and reduced efficacy of ketoconazole Details Lansoprazole Ledipasvir Decreased ledipasvir exposure and loss of efficacy Details Lansoprazole Levoketoconazole Recorlev Reduced levoketoconazole exposure Details Lansoprazole Lisdexamfetamine Arynta Increased exposure to amphetamine Details Lansoprazole Lonafarnib Zokinvy Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse effects Details Lansoprazole Methamphetamine Desoxyn Increased exposure to amphetamine Details Lansoprazole Methotrexate Jylamvo An increased methotrexate exposure, an increased risk of methotrexate-related severe adverse reactions, reduced active metabolite... Details Lansoprazole Methylphenidate Adhansia XR® Altered pharmacodynamic and changes in release profile of methylphenidate Details Lansoprazole Mycophenolate Mofetil Reduced mycophenolic acid exposure Details